FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

Approval Marks 11th BOTOX® Therapeutic Indication and Comes 30 Years After the First Indications Were Approved DUBLIN, Oct. 24, 2019 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug A... Biopharmaceuticals, FDA Allergan, BOTOX, onabotulinumtoxinA, limb spasticity
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news